CureVac NV (MIL:1CVAC)
€ 2.944 0.144 (5.14%) Market Cap: 682.36 Mil Enterprise Value: 167.57 Mil PE Ratio: 5.46 PB Ratio: 0.85 GF Score: 41/100

Q4 2020 CureVac NV Earnings Call Transcript

Apr 15, 2021 / 02:00PM GMT
Operator

Greetings, and welcome to the CureVac Fourth Quarter and Full Year 2020 Financial Results and Business Updates Conference Call. (Operator Instructions) As a reminder, this conference is being recorded.

It is now my pleasure to introduce Sarah Fakih, Head of Investor Relations. Thank you. You may begin.

Sarah Fakih
CureVac N.V. - VP of IR

Thank you. Good morning, good afternoon, and welcome to our conference call. My name is Sarah Fakih. I'm the Vice President of Investor Relations at CureVac.

Please let me introduce today's speakers. On the call with me are Franz Haas, the Chief Executive Officer of CureVac; Pierre Kemula, our Chief Financial Officer; and Ulrike Gnad-Vogt, our Interim Chief Development Officer. Mariola Fotin-Mleczek, the CureVac Chief Technology Officer will be available for the Q&A session after the presentation. Please note that this call is being webcast live and will be archived on the Events and Presentations section under Investor Relations on our website.

Before we begin a few forward-looking statements.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot